Nous tenons à remercier le personnel de l&#39;UCSF psoriasis et la peau Centre de traitement pour leur travail en particulier notre coordinateur Goeckerman, Sarah Hulse RN

1. Evaluation et préparation <ol><li> Effectuez une histoire complète et physique avant le début du traitement. Dans l&#39;histoire et le document d&#39;information physique, importantes, telles que les médicaments actuels / passés, la réponse aux traitements du psoriasis passé, des antécédents de réactions indésirables à la lumière du soleil ambiant ou à la photothérapie, la gravité du prurit, et la qualité du sommeil. </li><li> Mettre en place une salle de soins avec tout le matériel nécessaire pour l&#39;application cutanée de médicaments et d&#39;occlusion [Voir la section des matériaux et la figure 1]. Aussi, placer d&#39;autres matières dans la chambre tels que des gants, une pellicule de plastique, des chaussettes et des gommages / robes de pyjama. </li><li> Évaluer le patient pour érythème diffus et intense avant de commencer le traitement. </li><li> Si le patient présente un érythème généralisé ou intense, effectuer une procédure de &quot;cool down&quot; (voir ci-dessous) jusqu&#39;à ce que l&#39;érythème est considérablement réduit. Si aucun érythème généralisé ou intense est vu, passez à la &quot;+ photothérapie goudron&quot; étape. </li&gt; </ol> 2. Refroidir (si nécessaire) <ol><li> Appliquer les corticostéroïdes topiques dans les zones touchées. Appliquer triamcinolone 0,1% pommade au tronc et aux extrémités, desonide 0,05% crème / pommade sur le visage / aisselles / aine, et fluocinolone 0,01% d&#39;huile ou de triamcinolone 0,1% lotion sur le cuir chevelu. Réserve clobétasol 0,05% pommade pour les zones à l&#39;inflammation plus intense. </li><li> Obstruer les médicaments topiques avec une pellicule de plastique pour le tronc et les extrémités, des gants imperméables pour les bouchons de main et douche à l&#39;intérieur des chaussettes pour les pieds, et un bonnet de douche pour le cuir chevelu. </li><li> Refroidir le patient jusqu&#39;à la érythème est significativement réduite (plage de 3 à 14 jours). </li></ol> 3. Photothérapie + Tar <ol><li> Après que le patient se termine la période de refroidissement, administrer une photothérapie par jour le matin avant l&#39;application de goudron de houille brut [Figure 2]. Options de photothérapie UVB à bande étroite comprennent (la plus couramment utilisée dans psoriASIS) ou à large bande UVB (le plus couramment utilisé dans l&#39;eczéma). Déterminer la dose initiale de photothérapie par type de peau Fitzpatrick [voir tableaux 1 et 2]. </li><li> Titrer lentement les doses de photothérapie ultérieures vers le haut comme tolérés. Schéma posologique et le calendrier doivent être individualisés sur la base de la réponse du patient à la photothérapie. </li><li> Après photothérapie, appliquer 2% de goudron de houille brut (CCT) dans Aquaphor topique aux zones touchées du corps [Figure 3]. Si patiente est atteinte du cuir chevelu, appliquer 20% de liquide carbonis detergens (LCD) dans nutraderm sur le cuir chevelu. </li><li> Initialement, utiliser 2% CCT (force faible). Les jours de traitement ultérieures, augmenter la force du goudron comme tolérée par le patient de 2% à 5%, puis à 10% pour atteindre de meilleurs résultats. </li><li> Pour les zones épaissies de psoriasis, utilisez tar composé avec de l&#39;acide salicylique (2% / 5% / acide salicylique à 10%) pour aider à réduire l&#39;entartrage et induration des plaques. Initialement utiliser des préparations deL&#39;acide salicylique 2% avec 10% de CCT et doser le pourcentage de l&#39;acide salicylique en tant tolérée par le patient les jours suivants. L&#39;acide salicylique peut être contre-indiqué chez les patients souffrant de diabète ou ulcères gastriques. </li><li> Obstruer goudron actualité de la même manière que décrit dans l&#39;étape 2.2 pour le refroidissement procédure vers le bas. </li><li> Gardez les médicaments topiques sur la peau pendant au moins 4 heures. Après un minimum de 4 heures, retirer les matériaux d&#39;occlusion et laver le goudron dans la douche avec de l&#39;huile minérale et du savon [Figure 4]. </li><li> Donner au patient 20% en Aquaphor LCD et 20% dans nutraderm LCD à appliquer sur le corps et le cuir chevelu, respectivement, à la maison. </li><li> Les patients atteints d&#39;eczéma ont tendance à avoir la peau sensible. Utilisez 2% CCT initialement pour les patients atteints d&#39;eczéma. Soyez prudent lors de la titration jusqu&#39;à 5% de TDC, que les patients atteints d&#39;eczéma ont tendance à avoir la peau sensible. Ne pas utiliser 10% de CCT (ou tout pourcentage de CCT supérieure à 5%) et ne pas utiliser de préparations avec de l&#39;acide salicylique. </li></ol> 4.Évaluation quotidienne <ol><li> Chaque jour, effectuer une évaluation et d&#39;évaluer la peau et la réponse au traitement du patient. Évaluer spécifiquement pour les sensations de brûlure, qui peuvent indiquer l&#39;incapacité du patient à tolérer la luminothérapie, ou de démangeaisons, ce qui peut indiquer une irritation du goudron et / ou une pellicule plastique. </li><li> Si un patient présentait des signes de brûlure (sensation de brûlure, érythème augmentation significative, ou rarement augmenté démangeaison comme un signe avant-coureur de brûlure imminente si dosimétrie est encore augmentée), la dose de photothérapie diminution ou ne donnent pas photothérapie ce jour-là, car il peut avoir été causé par une réaction phototoxique à la dose de lumière UV précédente. </li><li> Il n&#39;est pas rare que les patients ont des réponses anatomiques régionales et la tolérance à la photothérapie. Pour un traitement optimal, ajuster la quantité de dose de photothérapie exposé à différentes régions du corps en fonction de la réponse du patient. Par exemple, si un patient subit une légère burnant du tronc, puis la première à traiter le corps entier avec la dose de photothérapie abaissée, que couvre le tronc, et de donner un éclairage supplémentaire aux extrémités. </li></ol> 5. Planification des sorties et maintenance <ol><li> Poursuivre le traitement jusqu&#39;à ce que la maladie Goeckerman est effacée et le patient est prêt à être déchargé. </li><li> Placer les patients sur un programme de maintenance, qui peuvent inclure photothérapie ambulatoire et des médicaments topiques </li><li> Administrer photothérapie ambulatoire trois fois par semaine (pour au moins le premier mois). Finalement, la fréquence est réduite progressivement jusqu&#39;à deux fois par semaine, puis une fois par semaine) </li><li> médicaments topiques ambulatoires comprennent: crème de triamcinolone / pommade sur le corps deux fois par jour, Clobétasol à des lésions récalcitrantes (si nécessaire) deux fois par jour, 20% de LCD dans Aquaphor pour le corps et 20% dans nutraderm LCD sur le cuir chevelu. </li><li> Moins d&#39;un mois de la sortie, planifier une visite de suivi du médecin avec le patient pour surveiller l&#39;état de la maladie. </li></ol>

<ol>
	<li>Parisi, R., Symmons, D. P., Griffiths, C. E., Ashcroft, D. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Global+Epidemiology+of+Psoriasis:+A+Systematic+Review+of+Incidence+and+Prevalence.">Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence.</a> The Journal of Investigative Dermatology. , (2012).</li><li>H, G. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+treatment+of+psoriasis.">The treatment of psoriasis.</a> Northwest Med. 24, 229-230 (1925).</li><li>Koo, J., Lebwohl, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Duration+of+remission+of+psoriasis+therapies.">Duration of remission of psoriasis therapies.</a> Journal of the American Academy of Dermatology. 41, 51-59 (1999).</li><li>Menter, A., Cram, D. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Goeckerman+regimen+in+two+psoriasis+day+care+centers.">The Goeckerman regimen in two psoriasis day care centers.</a> Journal of the American Academy of Dermatology. 9, 59-65 (1983).</li><li>Lee, E., Koo, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Modern+modified+'ultra'+Goeckerman+therapy:+a+PASI+assessment+of+a+very+effective+therapy+for+psoriasis+resistant+to+both+prebiologic+and+biologic+therapies.">Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.</a> The Journal of Dermatological Treatment. 16, 102-107 (2005).</li><li>Kim, I. H., West, C. E., Kwatra, S. G., Feldman, S. R., O'Neill, J. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparative+efficacy+of+biologics+in+psoriasis:+a+review.">Comparative efficacy of biologics in psoriasis: a review.</a> American journal of clinical dermatology. 13, 365-374 (2012).</li><li>Serrao, R., Davis, M. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Goeckerman+treatment+for+remission+of+psoriasis+refractory+to+biologic+therapy.">Goeckerman treatment for remission of psoriasis refractory to biologic therapy.</a> Journal of the American Academy of Dermatology. 60, 348-349 (2009).</li><li>Chern, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Positive+effect+of+modified+Goeckerman+regimen+on+quality+of+life+and+psychosocial+distress+in+moderate+and+severe+psoriasis.">Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis.</a> Acta Dermato-venereologica. 91, 447-451 (2011).</li><li>Dennis, M., Bhutani, T., Koo, J., Liao, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Goeckerman+therapy+for+the+treatment+of+eczema:+a+practical+guide+and+review+of+efficacy.">Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy.</a> The Journal of Dermatological Treatment. , (2011).</li><li>Papp, K. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Biologic+therapy+in+psoriasis:+perspectives+on+associated+risks+and+patient+management.">Biologic therapy in psoriasis: perspectives on associated risks and patient management.</a> Journal of Cutaneous Medicine and Surgery. 16, 153-168 (2012).</li><li>Menter, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Guidelines+of+care+for+the+management+of+psoriasis+and+psoriatic+arthritis:+Section+5.+Guidelines+of+care+for+the+treatment+of+psoriasis+with+phototherapy+and+photochemotherapy.">Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.</a> Journal of the American Academy of Dermatology. 62, 114-135 (2010).</li><li>de Miguel, R., el-Azhary, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Efficacy,+safety,+and+cost+of+Goeckerman+therapy+compared+with+biologics+in+the+treatment+of+moderate+to+severe+psoriasis.">Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis.</a> International Journal of Dermatology. 48, 653-658 (2009).</li><li>Busse, K., Koo, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Introducing+the+delayed+retinoid+burn:+a+case+report+and+discussion+of+this+potential+risk+of+retinoid-phototherapy+combination+management.">Introducing the delayed retinoid burn: a case report and discussion of this potential risk of retinoid-phototherapy combination management.</a> Journal of the American Academy of Dermatology. 64, 1011-1012 (2011).</li><li>Maughan, W. Z., Muller, S. A., Perry, H. O., Pittelkow, M. R., O'Brien, P. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Incidence+of+skin+cancers+in+patients+with+atopic+dermatitis+treated+with+ocal+tar.+A+25-year+follow-up+study.">Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study.</a> Journal of the American Academy of Dermatology. 3, 612-615 (1980).</li><li>Pittelkow, M. R., Perry, H. O., Muller, S. A., Maughan, W. Z., O'Brien, P. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Skin+cancer+in+patients+with+psoriasis+treated+with+coal+tar.+A+25-year+follow-up+study.">Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study.</a> Archives of Dermatology. 117, 465-468 (1981).</li><li>Roelofzen, J. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=No+increased+risk+of+cancer+after+coal+tar+treatment+in+patients+with+psoriasis+or+eczema.">No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema.</a> The Journal of Investigative Dermatology. 130, 953-961 (2010).</li></ol>

Dr Koo est un haut-parleur pour Abbott, Leo et Stiefel-GSK. Dr Koo mène des recherches pour Amgen, Janssen, Novartis, Photomedex, Galderma, et Pfizer. Dr Koo a pas de stocks, l&#39;emploi, ou les adhésions du conseil d&#39;administration avec une société pharmaceutique. Aucun conflit d&#39;intérêts divulgués à d&#39;autres auteurs.

Le protocole Régime Goeckerman décrite ci-dessus est utilisée à l&#39;UCSF et peut varier de plusieurs manières en fonction de la réponse du patient au traitement. Depuis le patient est vu et examiné tous les jours, le protocole peut être individualisée pour chaque patient afin d&#39;assurer une efficacité maximale. Le traitement Goeckerman traditionnelle uniquement composée de l&#39;utilisation de la CCT et la photothérapie UVB. 2 Toutefois, le régime a été modifié pour inclure l&#39;utilisat...

Le psoriasis est une maladie chronique, auto-immune inflammatoire cutanée qui touche environ 2-3% de la population. 1 Un tiers des patients souffrent de psoriasis généralisé qui provoque des effets physiques et psychologiques débilitantes. Le Goeckerman régime, d&#39;abord publié en 1925 pour le traitement du psoriasis généralisé, consiste en une exposition aux rayons ultraviolets B (UVB) la lumière et l&#39;application de goudron de houille brut (CCT). 2 Bien que les agents internes les plus récents comme les produits biologiques ont amélioré le traitement du psoriasis, thérapie Goeckerman reste aussi une option très efficace, tout en offrant une longue durée de rémission. 3,4 Dans une étude publiée menée à l&#39;UCSF, 100% des patients sous thérapie Goeckerman atteint PASI75 (75% d&#39;amélioration de l&#39;évaluation du psoriasis de l&#39;indice de gravité [PASI] la ligne de base) en 3 mois. 5 A titre de comparaison (mais pas en tête à tête), les patients sur les produits biologiques les plus puissants atteints que 67-68% PASI75 en 3 moisTHS. 6 Le régime Goeckerman a un début rapide et a été utilisé avec succès chez des patients atteints de psoriasis résistant au traitement réfractaires à la photothérapie ou interne médicaments. 7 Le régime Goeckerman a également un profil de toxicité extrêmement sûr avec pratiquement pas d&#39;effets secondaires internes, qui sont les risques les plus graves associés à d&#39;autres traitements du psoriasis. En outre, le traitement a été montré pour avoir un effet significatif et positif sur la qualité de vie des patients atteints de psoriasis généralisé. 8 Goeckerman régime était autrefois administrée 24 heures par jour dans un établissement hospitalier jusqu&#39;à ce que le patient a été effacé de leur psoriasis. Toutefois, en raison de changements dans les remboursements et la gestion des soins, les patients sont désormais traités dans des installations de garderie pour un minimum de 4-8 heures / jour, 5 jours / semaine jusqu&#39;à ce que leur maladie guérit. Traitement Goeckerman première formulation pour le traitement du psoriasis, mais une version modifiéea récemment été utilisé pour le traitement d&#39;autres affections de la peau comme l&#39;eczéma avec succès. Le protocole suivant est utilisé à l&#39;UCSF spécifiquement pour le psoriasis, mais de légers changements dans les procédures peuvent être adaptées pour l&#39;eczéma, prurit généralisé, prurigo nodulaire, le pityriasis lichénoïde chronique, érythrodermie, et d&#39;autres affections cutanées liées. 9 Bien qu&#39;il soit l&#39;une des thérapies les plus anciennes disponibles pour le psoriasis, il ya une absence de vidéos publiées démontrant le processus. Une vidéo peut avoir un large appel car il peut être utilisé comme une ressource pour renvoyer les praticiens de la santé (médecins de soins primaires et les dermatologues) pour comprendre le processus et de se sentir à l&#39;aise de recommander la thérapie. Une vidéo montrant le processus Goeckerman jouera également un rôle pour éduquer les résidents et étudiants en médecine qui ne sont pas exposées à la posologie car il ya seulement quelques institutions héritées qui continuent à fournir ce type d&#39;ithérapie ntensive. Une vidéo sera également bénéfique pour les patients potentiels qui sont intéressés à recevoir un traitement Goeckerman.

<table border="1">
	<tbody>
		<tr>
			<td>Name of Medication </td>
			<td>Company</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>2% Crude Coal Tar in White Petrolatum or Cetaphil</td>
			<td>Compounded at Pharmacy</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>5% Crude Coal Tar in White Petrolatum or Cetaphil</td>
			<td>Compounded at Pharmacy</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>10% Crude Coal Tar in White Petrolatum +/- 2/5/10% Salicyclic Acid</td>
			<td>Compounded at Pharmacy</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>10% Crude Coal Tar in Cetaphil</td>
			<td>Compounded at Pharmacy</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>20% Liquid Carbonis Detergenis in Nutraderm</td>
			<td>Compounded at Pharmacy</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>20% Liquid Carbonis Detergenis in Aquaphor or Cetaphil</td>
			<td>Compounded at Pharmacy</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Triamcinolone 0.1% ointment/cream/lotion</td>
			<td>Prescription Medication - Generic</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Desonide 0.05% cream/ointment</td>
			<td>Prescription Medication - Generic</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Fluocinolone 0.01% oil</td>
			<td>Prescription Medication - Generic</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Clobetasol 0.05% ointment/cream</td>
			<td>Prescription Medication - Generic</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Hydrophillic Ointment</td>
			<td>Over the Counter - Generic</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Mineral Oil</td>
			<td>Over the Counter - Generic</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Name of Equipment </td>
			<td>Company</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Narrow-Band Phototherapy Unit</td>
			<td>National Biologic Corporation</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Broad-Band Phototherapy Unit</td>
			<td>National Biologic Corporation</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
	</tbody>
</table>

the goeckerman regimen for the treatment of moderate to severe psoriasis

Le psoriasis est une maladie chronique, auto-immune inflammatoire cutanée qui touche environ 2-3% de la population. Le schéma Goeckerman consiste en une exposition aux rayons ultraviolets B (UVB) de lumière et de l&#39;application de goudron de houille brut (TDC). Goeckerman thérapie est très efficace et relativement sûr pour le traitement du psoriasis et de l&#39;amélioration de la qualité de vie du patient. Dans l&#39;article suivant, nous présentons notre protocole pour le traitement Goeckerman qui est utilisé spécifiquement à l&#39;Université de Californie, San Francisco. Détails Ce protocole de préparation de l&#39;approvisionnement, de l&#39;administration de la photothérapie et l&#39;application de goudron actualité. Ce protocole décrit également comment évaluer le patient par jour, surveiller les effets indésirables (y compris le prurit et brûlure), et ajuster le traitement en fonction de la réponse du patient. Bien qu&#39;il soit l&#39;une des thérapies les plus anciennes disponibles pour le psoriasis, il ya une absence de vidéos publiées démontrant le processus en détail. La vidéo est bénéfique pour les fournisseurs de soins de santé qui veulent administrer la thérapie, pour les stagiaires qui veulent en apprendre davantage sur le processus, et pour les patients potentiels qui veulent suivre un traitement pour leur maladie cutanée.

Dans une étude réalisée dans notre centre à l&#39;Université de Californie à San Francisco, PASI75 réponse (une amélioration de 75% dans l&#39;Indice de gravité de l&#39;évaluation du psoriasis) a été réalisée chez 100% des patients recevant Goeckerman (n = 25) pendant une période de 3 mois . 5 24/25 patients avaient besoin seulement 2 mois pour atteindre PASI75, alors que le patient restant obtenu une réponse PASI75 à 3 mois. Dans une autre étude, Menter et al. Administré le régi...

Watch this Scientific Journal Video about The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis at JoVE.com

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Le psoriasis est une maladie chronique inflammatoire de la peau, à médiation immunitaire. Le schéma Goeckerman, formulé pour le traitement du psoriasis, consiste en une exposition aux rayons ultraviolets B (UVB) de lumière et de l&#39;application de goudron de houille brut (TDC). Le protocole suivant est pour l&#39;administration de la thérapie Goeckerman pour le traitement du psoriasis modéré à sévère.

Le régime Goeckerman pour le traitement du psoriasis modéré à sévère

Psoriasis is a  chronic, immune-mediated inflammatory skin disease affecting approximately 2-3%  of the population. The Goeckerman regimen consists of ...

the-goeckerman-regimen-for-treatment-moderate-to-severe

Research

JoVE Journal

Medicine

38.7K vues.  University of Southern California. Le psoriasis est une maladie chronique inflammatoire de la peau, à médiation immunitaire. Le schéma Goeckerman, formulé pour le traitement du psoriasis, consiste en une exposition aux rayons ultraviolets B (UVB) de lumière et de l'application de goudron de houille brut (TDC). Le protocole suivant est pour l'administration de la thérapie Goeckerman pour le traitement du psoriasis modéré à sévère.

Vidéo: The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Bronchial Thermoplasty:  A Novel Therapeutic Approach to Severe Asthma

Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks. Bronchial thermoplasty is delivered by the Alair System and is performed in three outpatient procedure visits, each scheduled approximately three weeks apart. The first procedure treats the airways of the right lower lobe, the second treats the airways of the left lower lobe and the third and final procedure treats the airways in both upper lobes. After all three procedures are performed the bronchial thermoplasty treatment is complete.
Bronchial thermoplasty is performed during bronchoscopy with the patient under moderate sedation. All accessible airways distal to the mainstem bronchi between 3 and 10 mm in diameter, with the exception of the right middle lobe, are treated under bronchoscopic visualization. Contiguous and non-overlapping activations of the device are used, moving from distal to proximal along the length of the airway, and systematically from airway to airway as described previously. Although conceptually straightforward, the actual execution of bronchial thermoplasty is quite intricate and procedural duration for the treatment of a single lobe is often substantially longer than encountered during routine bronchoscopy. As such, bronchial thermoplasty should be considered a complex interventional bronchoscopy and is intended for the experienced bronchoscopist. Optimal patient management is critical in any such complex and longer duration bronchoscopic procedure. This article discusses the importance of careful patient selection, patient preparation, patient management, procedure duration, postoperative care and follow-up to ensure that bronchial thermoplasty is performed safely.
Bronchial thermoplasty is expected to complement asthma maintenance medications by providing long-lasting asthma control and improving asthma-related quality of life of patients with severe asthma. In addition, bronchial thermoplasty has been demonstrated to reduce severe exacerbations (asthma attacks) emergency rooms visits for respiratory symptoms, and time lost from work, school and other daily activities due to asthma.

Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks.

Thermoplastie bronchique: une nouvelle approche thérapeutique pour l&#39;asthme sévère

Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled ...

Recherche

Médecine

Thermal Ablation for the Treatment of Abdominal Tumors

Percutaneous thermal ablation is an emerging treatment option for many tumors of the abdomen not amenable to conventional treatments. During a thermal ablation procedure, a thin applicator is guided into the target tumor under imaging guidance. Energy is then applied to the tissue until temperatures rise to cytotoxic levels (50-60 &deg;C). Various energy sources are available to heat biological tissues, including radiofrequency (RF) electrical current, microwaves, laser light and ultrasonic waves. Of these, RF and microwave ablation are most commonly used worldwide.
During RF ablation, alternating electrical current (~500 kHz) produces resistive heating around the interstitial electrode. Skin surface electrodes (ground pads) are used to complete the electrical circuit. RF ablation has been in use for nearly 20 years, with good results for local tumor control, extended survival and low complication rates1,2. Recent studies suggest RF ablation may be a first-line treatment option for small hepatocellular carcinoma and renal-cell carcinoma3-5. However, RF heating is hampered by local blood flow and high electrical impedance tissues (eg, lung, bone, desiccated or charred tissue)6,7. Microwaves may alleviate some of these problems by producing faster, volumetric heating8-10. To create larger or conformal ablations, multiple microwave antennas can be used simultaneously while RF electrodes require sequential operation, which limits their efficiency. Early experiences with microwave systems suggest efficacy and safety similar to, or better than RF devices11-13.
Alternatively, cryoablation freezes the target tissues to lethal levels (-20 to -40 &deg;C). Percutaneous cryoablation has been shown to be effective against RCC and many metastatic tumors, particularly colorectal cancer, in the liver14-16. Cryoablation may also be associated with less post-procedure pain and faster recovery for some indications17. Cryoablation is often contraindicated for primary liver cancer due to underlying coagulopathy and associated bleeding risks frequently seen in cirrhotic patients. In addition, sudden release of tumor cellular contents when the frozen tissue thaws can lead to a potentially serious condition known as cryoshock 16.
Thermal tumor ablation can be performed at open surgery, laparoscopy or using a percutaneous approach. When performed percutaneously, the ablation procedure relies on imaging for diagnosis, planning, applicator guidance, treatment monitoring and follow-up. Ultrasound is the most popular modality for guidance and treatment monitoring worldwide, but computed tomography (CT) and magnetic resonance imaging (MRI) are commonly used as well. Contrast-enhanced CT or MRI are typically employed for diagnosis and follow-up imaging.

A thermal tumor ablation procedure is described. The entire procedure is detailed, including pretreatment planning and imaging studies, anesthesia, adjuvant techniques to facilitate a percutaneous approach, imaging guidance of the ablation device to the tumor, thermal treatment, post-treatment care and follow-up.

Ablation thermique pour le traitement des tumeurs abdominales

Percutaneous thermal ablation is an emerging treatment option for many tumors of the abdomen not amenable to conventional treatments. During a thermal ...

The Measurement and Treatment of Suppression in Amblyopia

Amblyopia, a developmental disorder of the visual cortex, is one of the leading causes of visual dysfunction in the working age population. Current estimates put the prevalence of amblyopia at approximately 1-3%1-3, the majority of cases being monocular2. Amblyopia is most frequently caused by ocular misalignment (strabismus), blur induced by unequal refractive error (anisometropia), and in some cases by form deprivation.
Although amblyopia is initially caused by abnormal visual input in infancy, once established, the visual deficit often remains when normal visual input has been restored using surgery and/or refractive correction. This is because amblyopia is the result of abnormal visual cortex development rather than a problem with the amblyopic eye itself4,5 . Amblyopia is characterized by both monocular and binocular deficits6,7 which include impaired visual acuity and poor or absent stereopsis respectively. The visual dysfunction in amblyopia is often associated with a strong suppression of the inputs from the amblyopic eye under binocular viewing conditions8. Recent work has indicated that suppression may play a central role in both the monocular and binocular deficits associated with amblyopia9,10 .
Current clinical tests for suppression tend to verify the presence or absence of suppression rather than giving a quantitative measurement of the degree of suppression. Here we describe a technique for measuring amblyopic suppression with a compact, portable device11,12 . The device consists of a laptop computer connected to a pair of virtual reality goggles. The novelty of the technique lies in the way we present visual stimuli to measure suppression. Stimuli are shown to the amblyopic eye at high contrast while the contrast of the stimuli shown to the non-amblyopic eye are varied. Patients perform a simple signal/noise task that allows for a precise measurement of the strength of excitatory binocular interactions. The contrast offset at which neither eye has a performance advantage is a measure of the "balance point" and is a direct measure of suppression. This technique has been validated psychophysically both in control13,14 and patient6,9,11 populations.
In addition to measuring suppression this technique also forms the basis of a novel form of treatment to decrease suppression over time and improve binocular and often monocular function in adult patients with amblyopia12,15,16 . This new treatment approach can be deployed either on the goggle system described above or on a specially modified iPod touch device15.

Amblyopia is a developmental disorder of the visual cortex that is often accompanied by strong suppression of one eye. We present a new technique for measuring and treating interocular suppression in patients with amblyopia that can be deployed using virtual reality goggles or a portable iPod Touch device.

La mesure et le traitement de répression dans l&#39;amblyopie

Amblyopia, a developmental disorder of the visual cortex, is one of the leading causes of visual dysfunction in the working age population. Current ...

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Diseases of the retina are difficult to treat as the retina lies deep within the eye. Invasive methods of drug delivery are often needed to treat these diseases. Chronic retinal diseases such as retinal oedema or neovascularization usually require multiple intraocular injections to effectively treat the condition. However, the risks associated with these injections increase with repeated delivery of the drug. Therefore, alternative delivery methods need to be established in order to minimize the risks of reinjection. Several other investigations have developed methods to deliver drugs over extended time, through materials capable of releasing chemicals slowly into the eye. In this investigation, we outline the use of Elvax 40W, a copolymer resin, to act as a vehicle for drug delivery to the adult rat retina. The resin is made and loaded with the drug. The drug-resin complex is then implanted into the vitreous cavity, where it will slowly release the drug over time. This method was tested using 2-amino-4-phosphonobutyrate (APB), a glutamate analogue that blocks the light response of the retina. It was demonstrated that the APB was slowly released from the resin, and was able to block the retinal response by 7 days after implantation. This indicates that slow-release drug delivery using this copolymer resin is effective for treating the retina, and could be used therapeutically with further testing.

This paper details how Elvax 40W can be used as a slow-release method for drug delivery to the adult rat retina. The protocol for preparing, loading, and delivering the drug-resin complex to the eye is described.

À libération lente Drug Delivery par Elvax 40W pour le Retina Rat: Implications pour le traitement des maladies chroniques

Diseases of the retina are difficult to treat as the retina lies deep within the eye. Invasive methods of drug delivery are often needed to treat these ...

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Approximately 30% of epilepsy patients are refractory to antiepileptic drugs. In these cases, surgery is the only alternative to eliminate/control seizures. However, a significant minority of patients continues to exhibit post-operative seizures, even in those cases in which the suspected source of seizures has been correctly localized and resected. The protocol presented here combines a clinical procedure routinely employed during the pre-operative evaluation of temporal lobe epilepsy (TLE) patients with a novel technique for network analysis. The method allows for the evaluation of the temporal evolution of mesial network parameters. The bilateral insertion of foramen ovale electrodes (FOE) into the ambient cistern simultaneously records electrocortical activity at several mesial areas in the temporal lobe. Furthermore, network methodology applied to the recorded time series tracks the temporal evolution of the mesial networks both interictally and during the seizures. In this way, the presented protocol offers a unique way to visualize and quantify measures that considers the relationships between several mesial areas instead of a single area.

This protocol describes a procedure to track the evolution of mesial network measures in temporal lobe epilepsy (TLE) patients. It is based on the combination of intracranial recordings with a novel numerical technique for data analysis. Specifically, we present a protocol for network analyses of foramen ovale recordings.

Analyse du réseau de foramen ovale électrodes Recordings en résistant aux médicaments épilepsies temporales patients

Approximately 30% of epilepsy patients are refractory to antiepileptic drugs. In these cases, surgery is the only alternative to eliminate/control ...

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Removable dentures made of poly (methyl methacrylate) (PMMA) are prone to bacterial adherence and dental plaque formation, which is called denture plaque. Denture plaque-associated infection is a source of serious dental and medical complications in the elderly. 2-Methacryloyloxyethyl phosphorylcholine (MPC) is a well-known biomedical material that exhibits marked antithrombogenicity and tissue compatibility because of its high resistance to protein adsorption and cell adhesion. Therefore, MPC polymer coatings are suggested to have the potential to inhibit plaque deposition on the surface of PMMA dentures. However, coating MPC polymer on the surface of a PMMA denture is a complex procedure that requires specialized equipment, which is regarded as a major barrier to its clinical application. 
Here, we introduce a new MPC polymer treatment procedure that uses poly (MPC-co-BMA-co-MPAz) (PMBPAz) to prevent denture plaque deposition on removable dentures. This procedure enables the MPC coating of PMMA denture surfaces in a simple and stable manner that is resistant to various chemical and mechanical stresses due to the MPC layer of PMBPAz that is covalently bound to the PMMA surface by ultraviolet light irradiation. In addition, the procedure does not require any specialized equipment and can be completed by clinicians within 2 min. We applied this procedure in a clinical setting and demonstrated its clinical utility and efficacy in inhibiting plaque deposition on removable dentures.

Removable poly(methyl methacrylate) (PMMA) dentures are prone to bacterial adherence and plaque formation. Denture plaque-associated infection is a source of serious dental and medical complications in the elderly. This paper introduces a novel protocol to treat PMMA dentures with 2-methacryloyloxyethyl phosphorylcholine polymer, poly(MPC-co-BMA-co-MPAz), to suppress plaque deposition on PMMA dentures.

2-méthacryloyloxyéthyl phosphorylcholine Traitement Polymer des dentiers complets à Inhibition Denture Plaque Deposition

Removable dentures made of poly (methyl methacrylate) (PMMA) are prone to bacterial adherence and dental plaque formation, which is called denture plaque. ...

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Dry eye disease (DED) is an increasingly common condition and one of the most common complaints of patients. The vast majority of DED is caused by the so-called &#34;evaporative&#34; subtype, that is mainly caused by meibomian gland dysfunction (MGD). Intense pulsed light (IPL) devices employ high intensity pulses of polychromatic lights with a broad range of wavelength (515-1200 nm). IPL treatment has been utilized for years in the field of dermatology, and then its use was applied to ophthalmology for the treatment of MGD. Recently, a new device employing IPL was specifically designed for the periocular application. This procedure determines the thermal selective coagulation and ablation of superficial blood vessels and telangiectasias of the eyelids skin, reducing the release of inflammatory mediators and tear cytokines levels, and improving meibomian glands outflow. IPL treatment is noninvasive and easy to perform, lasts for only a few minutes and can be conducted in an office setting. In the present study, 19 patients underwent 3 sessions of IPL treatment. After treatment, both mean noninvasive break-up time and lipid layer thickness grade significantly increased, as a result of an improvement of tear film stability and quality, respectively. Conversely, no statistically significant changes were found for meibomian gland loss and tear osmolarity. Furthermore, the vast majority of the treated patients (17/19; 89.5% of the total) perceived an improvement of their ocular discomfort symptoms after IPL treatment. Although IPL treatment provides an improvement of both ocular surface parameters and ocular discomfort symptoms after one cycle of three sessions, regular repeated treatments are usually required to maintain the persistence over the time of its beneficial effects.

Dry eye disease is an increasingly common condition, which strongly impair patients&#39; life quality. Recently, a new device employing intense pulsed light, specifically designed for the periocular area, has been shown to improve tear film stability and ocular discomfort symptoms in dry eye disease owing to meibomian gland dysfunction.

Intense lumière pulsée pour le traitement de la sécheresse oculaire en raison de dysfonctionnement des glandes de Meibomius

Dry eye disease (DED) is an increasingly common condition and one of the most common complaints of patients. The vast majority of DED is caused by the ...

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct

The prevalence of acute pancreatitis (AP), especially severe acute pancreatitis (SAP), is increasing in younger age groups annually. However, there is a lack of effective treatments in the current clinical practice. With the easy accessibility of transgenic and knockout strains and their small size, which allows minimal doses of drugs required for in vivo evaluation, a well-established experimental model in mice is preferred for AP research. Moreover, SAP induced through sodium taurocholate (TC) is currently one of the most widely used and best characterized models. This model has been investigated for novel therapies and possible molecular events during the process of AP. Here, we present the generation of an AP mouse model using sodium taurocholate and a simple homemade microsyringe. Moreover, we also provide the methodology for the subsequent histology and serological testing.

A mouse model of severe acute pancreatitis is described herein. The procedure presented here is very rapid, simple, and accessible, thereby potentially allowing the study of the molecular mechanisms and different therapeutic interventions in acute pancreatitis in a convenient way.

Établissement d’un modèle de pancréatite aiguë sévère chez la souris par injection rétrograde de taurocholate de sodium dans le canal biliopancréatique

The prevalence of acute pancreatitis (AP), especially severe acute pancreatitis (SAP), is increasing in younger age groups annually. However, there is a ...

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors

In view of the shortcomings of endoscopic or laparoscopic surgeries alone in the treatment of gastric gastrointestinal stromal tumors (G-GISTs), this approach makes an innovative improvement in the treatment of G-GISTs that are less than 5 cm in size. Laparoscopy-endoscopy cooperative surgery (LECS) is used to combine endoscopic and laparoscopic surgeries, fully realizing their respective advantages and avoiding their drawbacks. The main steps are as follows. First, gastroscopy and laparoscopy are combined to confirm the location and boundary of the tumor. Tumor resection is carried out laparoscopically, guided by a gastroscope. The specimen is removed orally and the gastric wound closed laparoscopically. Then, gastroscopy and laparoscopy are combined to determine whether there is wound bleeding, if the suture is satisfactory, and if the gastric cavity is deformed.
LECS has natural advantages in the treatment of G-GISTs that are less than 5 cm in size. The accurate estimation of tumor location and boundary greatly improves the complete resection rate of tumors. The risk of tumor rupture is substantially reduced, and the long-term prognosis of patients is significantly improved. The process allows for accurate resection of the tumor, maximum preservation of normal gastric tissue and organ function, and avoids postoperative gastric deformation. The patient's postoperative rehabilitation is greatly accelerated, and oral feeding can resume on the day of the operation. The specimen is taken out through the mouth to avoid the need for an extended abdominal incision. This greatly reduces the patient's postoperative pain and scarring. The method greatly shortens the postoperative hospital stay (i.e., discharge is possible on the day after the operation), increasing the turnover of hospital beds.

Laparoscopy-endoscopy cooperative surgery is appropriate for the treatment of gastric gastrointestinal stromal tumors less than 5 cm in size. It can achieve the respective advantages of endoscopic and laparoscopic surgeries while avoiding their drawbacks.

Laparoscopie-endoscopie Chirurgie coopérative pour le traitement des tumeurs stromales gastro-intestinales gastriques

In view of the shortcomings of endoscopic or laparoscopic surgeries alone in the treatment of gastric gastrointestinal stromal tumors (G-GISTs), this ...

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst

Epididymal cysts mostly occur in men aged 20-40 years old. Previous reports have covered concerns about postoperative complexes, including postoperative asoedema, hematoma, sustaining pain, and seminal tract obstruction in patients who have undertaken nonmicroscopic epididymal cyst resection or epididymal resection. Nonmicroscopic epididymal cyst surgery is suggested for patients with childbirth plans as a precaution. The treatment of male epididymal cysts via microtechnology is obviously a beneficial option; we took the lead in carrying out microscopic epididymal exploration and cyst resection surgery in China. From September 2017 to April 2021, 41 young and middle-aged male patients diagnosed with epididymal cysts underwent microtechnology treatment in a program titled &#34;microscopic epididymal exploration and cystectomy&#34;. The postoperative follow-up lasted for 3-50 months. The results confirmed that, as microscopic manipulation largely improved visualization of the subtle tissue structures of the epididymis, the cyst could be clearly dissected apart and completely removed intact under the microscope. Bleeding during the operation was significantly reduced (2-3 mL) and wound drainage was not required. According to follow-up data, microscopic treatment significantly reduced the incidence of postoperative scrotal hematoma, edema, and long-term postoperative pain, thereby promising a higher surgical success rate as well as recurrence prevention. Besides, preliminary experience and reflection suggest that microscopic epididymal exploration and cystectomy provide efficient preservation of the epididymal patency through refined treatment, while a better prognosis can be achieved. We recommend that surgery be carried out before the epididymal cyst develops to 0.8 cm in diameter, for fear that a larger epididymal cyst (&#62;0.9 cm in diameter) could cause the complete destruction of all tubules of the ipsilateral epididymis - a more severe case with damage to the testicular output network.

Here, we present a protocol to treat patients diagnosed with an epididymal cyst using microscopic cyst resection. Based on microscopic manipulation, a largely improved visualization of the subtle tissue structures of the epididymis was obtained, so the cyst could be clearly dissected apart and completely removed intact.

Résection microscopique de kystes pour le traitement des patients diagnostiqués avec un kyste épididymaire

Epididymal cysts mostly occur in men aged 20-40 years old. Previous reports have covered concerns about postoperative complexes, including postoperative ...